Latest Alzheimer's disease Stories

- Alzheimer's Association Statement - WASHINGTON, Jan. 14, 2013 /PRNewswire-USNewswire/ -- Today the Advisory Council on Alzheimer's Research, Care, and Services approved recommendations to best address the Alzheimer's crisis. Those recommendations included efforts to bolster the development of new treatments that prevent or effectively treat Alzheimer's by 2025, strengthen and expand the delivery of much needed support for families, and enhance care quality and effectiveness. The...

SAN DIEGO, Jan. 14, 2013 /PRNewswire-USNewswire/ -- People taking the blood pressure drugs called beta blockers may be less likely to have changes in the brain that can be signs of Alzheimer's disease and other types of dementia, according to a study that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. The study involved 774 elderly Japanese-American men who took part in the Honolulu-Asia Aging Study. Autopsies were...

VANCOUVER, Jan. 10, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) announces the appointment of Athanasios (Tom) Skarpelos as a Director of the company effective January 9, 2013. "Tom has been actively involved in Anavex since the very beginning," said Sean Lowry, former Director of Anavex. "His passion for Anavex and its assets, and his relationships with people and organizations close to the company have characterized the company's development since...

Rayshell Clapper for redOrbit.com - Your Universe Online Information released Monday, January 7, shows that there may be a connection between taking the blood pressure drugs beta blockers and a reduced risk for Alzheimer’s disease and other types of dementia. 774 elderly Japanese-American men participated in the Honolulu-Asia Aging Study. After the men died, autopsies were performed to check their heart and brain health and the connection therein. 610 of the 774 participants had high...

Two new approaches to treating Alzheimer’s disease offer hope for meaningful treatment in the near future. Boston, MA (PRWEB) January 05, 2013 Harvard doctors are testing two new approaches to Alzheimer's disease aimed at reversing the condition or its symptoms, reports the January 2013 Harvard Health Letter. Dr. Rudy Tanzi helped create a drug called PBT2. It prevents the production of protein plaques and tangles that kill brain cells. "It also induces new neurons to grow in...

CHERRY HILL, N.J., Jan. 4, 2013 /PRNewswire/ -- With the nation focusing increasing attention on Alzheimer's disease as a major public health crisis, families in the Cherry Hill area will have the opportunity to get educated about how to cope with a disease that can carry a devastating diagnosis for the entire family. On Thursday, January 10(th) , the Alzheimer's Foundation of America (AFA), a leading national nonprofit organization, and Senior Helpers, one of the nation's largest...

Some brain changes that are found in adults with common gene variants linked to disorders such as Alzheimer's disease, schizophrenia, and autism can also be seen in the brain scans of newborns. "These results suggest that prenatal brain development may be a very important influence on psychiatric risk later in life," said Rebecca C. Knickmeyer, PhD, lead author of the study and assistant professor of psychiatry in the University of North Carolina School of Medicine. The study was published...

Connie K. Ho for redOrbit.com – Your Universe Online Scientists from the National Institutes of Health (NIH) recently tested a promising new compound that could help reverse symptoms of Alzheimer’s disease and restore memory in laboratory mice. Alzheimer’s is a form of degenerative dementia that can affect behavior, memory and thinking. While there is currently no cure, researchers continue to look at treatments for symptoms of the disease. The findings of the study were...

LA CHAUX-DE-FONDS, Switzerland, January 3, 2013 /PRNewswire/ -- ~ Following US IND approval, Phase I trial to assess safety, tolerability and pharmacokinetics of KU-046 in healthy young volunteers ~ Kareus Therapeutics SA ("Kareus" or the "Company"), the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study...

See me, not my disease. Let's talk about dementia. TORONTO, Jan. 2, 2013 /CNW/ - Imagine a close friend tells you she has dementia. Would you avoid her for fear of being embarrassed by what she might say or do? According to a recent poll by Alzheimer's Disease International, 40 per cent of people with dementia reported they had been avoided or treated differently after diagnosis. It's no surprise, then, that one in four respondents cited stigma as a reason to conceal their...